Evidence map›Paper›PMID 39589530›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment.

Uttam Singh Baghel, Priyanka Kriplani, Neelam M Patel, Manpreet Kaur, Kapil Sharma, Monika Meghani, Abhay Sharma, Deeksha Singh, Bhawani Singh, William N Setzer and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Isolation and Characterization of 5-(1-Hydroxyethyl)-Dihydro-2-Furanone fromInternational journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Uttam Singh BaghelGurukul Pharmacy College, Ranpur, 325003, Kota, India.
Priyanka KriplaniGuru Gobind Singh College of Pharmacy, Yamuna Nagar, 135001, India.
Neelam M PatelGurukul Pharmacy College, Ranpur, 325003, Kota, India.
Manpreet KaurGurukul Pharmacy College, Ranpur, 325003, Kota, India.
Kapil SharmaGurukul Pharmacy College, Ranpur, 325003, Kota, India.
Monika MeghaniGurukul Pharmacy College, Ranpur, 325003, Kota, India.
Abhay SharmaDepartment of Pharmacy, University of Kota, Kota, 324005, Rajasthan, India.
Deeksha SinghE. S. I. Hospital, 324005, Kota, Rajasthan, India.
Bhawani SinghDeparment of Pure and Applied Chemistry, University of Kota, Kota, 324005, India.
William N SetzerAromatic Plant Research Center, 230 N 1200 E, Suite 100, Lehi, UT, 84043, USA.
Javad Sharifi-RadUniversidad Espíritu Santo, Samborondón, Ecuador. javad.sharifirad@gmail.com.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flavopiridol, a synthetic flavonoid derived from rohitukine, stands out as a powerful cyclin-dependent kinase (CDK) inhibitor with significant anticancer properties. Its action mechanisms involve inducing cell cycle arrest, triggering apoptosis, and inhibiting transcription across various cancer types. Despite these promising effects, flavopiridol's clinical use has been hampered by issues related to toxicity and drug resistance. This study aims to comprehensively review flavopiridol's mechanisms of action, structure-activity relationships, synthetic derivatives, pharmacokinetics, and its potential role in clinical applications, with a focus on how combination therapies can enhance its efficacy and address resistance challenges in cancer treatment. A thorough analysis of key studies was performed, examining flavopiridol's anticancer properties, emphasizing its structure-activity relationships, synthetic modifications, and clinical outcomes. The anticancer effects of flavopiridol are primarily driven by its inhibition of CDKs, induction of apoptosis, promotion of oxidative stress, and antiangiogenic activity. Modifications in its chemical structure, especially in the D ring, have shown a significant impact on its CDK inhibitory potency. Several synthetic derivatives have also demonstrated enhanced anticancer activity. While preclinical models highlight flavopiridol's potential in treating cancers such as leukemia and solid tumors, clinical trials have brought attention to its limitations, particularly regarding toxicity and resistance. However, flavopiridol remains a promising candidate for cancer therapy, especially when used in combination with other treatments. Future research efforts should focus on refining its therapeutic profile, minimizing toxicity, and investigating synergistic treatment combinations, including those with immunotherapy. Understanding the mechanisms of resistance and discovering predictive biomarkers will be crucial for its effective integration into clinical practice.

Indexed as

Antineoplastic AgentsCyclin-Dependent KinasesFlavonoidsNeoplasmsPiperidinesProtein Kinase InhibitorsAnimalsApoptosisDrug Resistance, NeoplasmHumansStructure-Activity RelationshipalvocidibAntineoplastic AgentsCyclin-Dependent KinasesFlavonoidsPiperidinesProtein Kinase InhibitorsAnticancerCyclin-dependent kinase inhibitorFlavopiridolPharmacokineticsStructure–activity relationshipSynthetic derivatives

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.